Basudev Chowdhury1, Il-Hoon Cho2, Noah Hahn3, Joseph Irudayaraj4. 1. Bindley Bioscience & Birck Nanotechnology Center, Department of Agricultural & Biological Engineering, Purdue University, 225 South University Street, West Lafayette, IN 47907, USA. 2. Bindley Bioscience & Birck Nanotechnology Center, Department of Agricultural & Biological Engineering, Purdue University, 225 South University Street, West Lafayette, IN 47907, USA; Dept. of Biomedical Laboratory Science, College of Health Science, Eulji University, Seongnam 461-713, Republic of Korea. 3. Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA. 4. Bindley Bioscience & Birck Nanotechnology Center, Department of Agricultural & Biological Engineering, Purdue University, 225 South University Street, West Lafayette, IN 47907, USA. Electronic address: josephi@purdue.edu.
Abstract
BACKGROUND: Genome-wide aberrations of the classic epigenetic modification 5-methylcytosine (5mC), considered the hallmark of gene silencing, has been implicated to play a pivotal role in mediating carcinogenic transformation of healthy cells. Recently, three epigenetic marks derived from enzymatic oxidization of 5mC namely 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), have been discovered in the mammalian genome. Growing evidence suggests that these novel bases possess unique regulatory functions and may play critical roles in carcinogenesis. METHODS: To provide a quantitative basis for these rare epigenetic marks, we have designed a biotin-avidin mediated enzyme-based immunoassay (EIA) and evaluated its performance in genomic DNA isolated from blood of patients diagnosed with metastatic forms of lung, pancreatic and bladder cancer, as well as healthy controls. The proposed EIA incorporates spatially optimized biotinylated antibody and a high degree of horseradish-peroxidase (HRP) labeled streptavidin, facilitating signal amplification and sensitive detection. RESULTS: We report that the percentages of 5mC, 5hmC and 5caC present in the genomic DNA of blood in healthy controls as 1.025±0.081, 0.023±0.006 and 0.001±0.0002, respectively. We observed a significant (p<0.05) decrease in the mean global percentage of 5hmC in blood of patients with malignant lung cancer (0.013±0.003%) in comparison to healthy controls. CONCLUSION: The precise biological roles of these epigenetic modifications in cancers are still unknown but in the past two years it has become evident that the global 5hmC content is drastically reduced in a variety of cancers. To the best of our knowledge, this is the first report of decreased 5hmC content in the blood of metastatic lung cancer patients and the clinical utility of this observation needs to be further validated in larger sample datasets.
BACKGROUND: Genome-wide aberrations of the classic epigenetic modification 5-methylcytosine (5mC), considered the hallmark of gene silencing, has been implicated to play a pivotal role in mediating carcinogenic transformation of healthy cells. Recently, three epigenetic marks derived from enzymatic oxidization of 5mC namely 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), have been discovered in the mammalian genome. Growing evidence suggests that these novel bases possess unique regulatory functions and may play critical roles in carcinogenesis. METHODS: To provide a quantitative basis for these rare epigenetic marks, we have designed a biotin-avidin mediated enzyme-based immunoassay (EIA) and evaluated its performance in genomic DNA isolated from blood of patients diagnosed with metastatic forms of lung, pancreatic and bladder cancer, as well as healthy controls. The proposed EIA incorporates spatially optimized biotinylated antibody and a high degree of horseradish-peroxidase (HRP) labeled streptavidin, facilitating signal amplification and sensitive detection. RESULTS: We report that the percentages of 5mC, 5hmC and 5caC present in the genomic DNA of blood in healthy controls as 1.025±0.081, 0.023±0.006 and 0.001±0.0002, respectively. We observed a significant (p<0.05) decrease in the mean global percentage of 5hmC in blood of patients with malignant lung cancer (0.013±0.003%) in comparison to healthy controls. CONCLUSION: The precise biological roles of these epigenetic modifications in cancers are still unknown but in the past two years it has become evident that the global 5hmC content is drastically reduced in a variety of cancers. To the best of our knowledge, this is the first report of decreased 5hmC content in the blood of metastatic lung cancerpatients and the clinical utility of this observation needs to be further validated in larger sample datasets.
Authors: N Konstandin; S Bultmann; A Szwagierczak; A Dufour; B Ksienzyk; F Schneider; T Herold; M Mulaw; P M Kakadia; S Schneider; K Spiekermann; H Leonhardt; S K Bohlander Journal: Leukemia Date: 2011-05-31 Impact factor: 11.528
Authors: M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman Journal: J Natl Cancer Inst Date: 2000-04-05 Impact factor: 13.506
Authors: Steve D Knutson; Robert A Arthur; H Richard Johnston; Jennifer M Heemstra Journal: Angew Chem Int Ed Engl Date: 2021-06-28 Impact factor: 16.823
Authors: Basudev Chowdhury; Andrew McGovern; Yi Cui; Samrat Roy Choudhury; Il-Hoon Cho; Bruce Cooper; Timothy Chevassut; Amy C Lossie; Joseph Irudayaraj Journal: Sci Rep Date: 2015-04-22 Impact factor: 4.379
Authors: Pushpak N Bhandari; Yi Cui; Bennett D Elzey; Craig J Goergen; Christopher M Long; Joseph Irudayaraj Journal: Sci Rep Date: 2017-08-24 Impact factor: 4.379
Authors: Maria Eleftheriou; Ana Jimenez Pascual; Lee M Wheldon; Christina Perry; Abdulkadir Abakir; Arvind Arora; Andrew D Johnson; Dorothee T Auer; Ian O Ellis; Srinivasan Madhusudan; Alexey Ruzov Journal: Clin Epigenetics Date: 2015-08-21 Impact factor: 6.551